Meeting
2022 ASCO Annual Meeting
Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms.
Authors
Thomas J. George
The University of Florida Health Cancer Center, Gainesville, FL
Thomas J. George , Ji-Hyun Lee , Peter Joel Hosein , David L. DeRemer , Jonathan Alexander Chatzkel , Brian Hemendra Ramnaraign , Sherise C. Rogers , Merry Jennifer Markham , Karen Colleen Daily , Nkiruka Ezenwajiaku , Derek Li , Martina Cathryn Murphy , Aaron J Franke , Stephen Staal , Julia Lee Close , Dennie V. Jones , Carmen Joseph Allegra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
NCT03207347
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3122)
DOI
10.1200/JCO.2022.40.16_suppl.3122
Abstract #
3122
Poster Bd #
114
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
First Author: Thomas J. George
Poster
2017 ASCO Annual Meeting
Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.
First Author: Ecaterina Elena Ileana Dumbrava
Poster
2023 ASCO Annual Meeting
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).
First Author: Anup Kasi
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan